格伦马克的AkynzeoI. V. 这表明在减少化学诱发的恶心和呕吐方面,现实世界取得了积极的成果。 Glenmark's Akynzeo I.V. shows positive real-world results in reducing chemo-induced nausea and vomiting.

Clini专家已完成关于Akynzeo I.V.的第四阶段临床研究。 Akynzeo I.V.是格伦马克制药公司治疗化疗引起的恶心和呕吐的治疗。 CliniExperts has completed a Phase IV clinical study on Akynzeo I.V., a treatment for chemotherapy-induced nausea and vomiting, for Glenmark Pharmaceuticals. 这项研究侧重于现实世界的有效性和安全性,在多个中心进行,涉及接受化疗的患者。 The study, which focused on real-world effectiveness and safety, was conducted across multiple centers and involved patients receiving chemotherapy. 预计结果将支持药物的监管和临床持续使用。 Results are expected to support ongoing regulatory and clinical use of the drug.